vs
渤健（BIIB）与国民油井华高（NOV）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是国民油井华高的1.1倍（$2.3B vs $2.1B），国民油井华高净利率更高（1.0% vs -2.1%，领先3.1%），渤健同比增速更快（-7.1% vs -9.9%），渤健自由现金流更多（$468.0M vs $51.0M），过去两年渤健的营收复合增速更高（-0.2% vs -3.8%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
NOV Inc.（前称国民油井华高）是总部位于美国得克萨斯州休斯顿的跨国企业，为上游油气行业提供钻探及生产作业所需的设备零部件、油田服务及供应链整合服务，在六大洲布局超500个运营点，下设能源设备、能源产品与服务两大业务板块。
BIIB vs NOV — 直观对比
营收规模更大
BIIB
是对方的1.1倍
$2.1B
营收增速更快
BIIB
高出2.7%
-9.9%
净利率更高
NOV
高出3.1%
-2.1%
自由现金流更多
BIIB
多$417.0M
$51.0M
两年增速更快
BIIB
近两年复合增速
-3.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $2.1B |
| 净利润 | $-48.9M | $20.0M |
| 毛利率 | 78.3% | 18.5% |
| 营业利润率 | -2.5% | 2.3% |
| 净利率 | -2.1% | 1.0% |
| 营收同比 | -7.1% | -9.9% |
| 净利润同比 | -118.3% | -73.0% |
| 每股收益（稀释后） | $-0.35 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBNOV
| Q1 26 | — | $2.1B | ||
| Q4 25 | $2.3B | $2.3B | ||
| Q3 25 | $2.5B | $2.2B | ||
| Q2 25 | $2.6B | $2.2B | ||
| Q1 25 | $2.4B | $2.1B | ||
| Q4 24 | $2.5B | $2.3B | ||
| Q3 24 | $2.5B | $2.2B | ||
| Q2 24 | $2.5B | $2.2B |
净利润BIIBNOV
| Q1 26 | — | $20.0M | ||
| Q4 25 | $-48.9M | $-78.0M | ||
| Q3 25 | $466.5M | $42.0M | ||
| Q2 25 | $634.8M | $108.0M | ||
| Q1 25 | $240.5M | $73.0M | ||
| Q4 24 | $266.7M | $160.0M | ||
| Q3 24 | $388.5M | $130.0M | ||
| Q2 24 | $583.6M | $226.0M |
毛利率BIIBNOV
| Q1 26 | — | 18.5% | ||
| Q4 25 | 78.3% | 20.3% | ||
| Q3 25 | 73.4% | 18.9% | ||
| Q2 25 | 77.1% | 20.4% | ||
| Q1 25 | 74.1% | 21.3% | ||
| Q4 24 | 76.2% | 21.4% | ||
| Q3 24 | 74.1% | 21.4% | ||
| Q2 24 | 77.8% | 26.6% |
营业利润率BIIBNOV
| Q1 26 | — | 2.3% | ||
| Q4 25 | -2.5% | 4.0% | ||
| Q3 25 | 22.0% | 4.9% | ||
| Q2 25 | 28.1% | 6.5% | ||
| Q1 25 | 12.8% | 7.2% | ||
| Q4 24 | 11.9% | 9.0% | ||
| Q3 24 | 18.3% | 8.9% | ||
| Q2 24 | 28.3% | 14.1% |
净利率BIIBNOV
| Q1 26 | — | 1.0% | ||
| Q4 25 | -2.1% | -3.4% | ||
| Q3 25 | 18.4% | 1.9% | ||
| Q2 25 | 24.0% | 4.9% | ||
| Q1 25 | 9.9% | 3.5% | ||
| Q4 24 | 10.9% | 6.9% | ||
| Q3 24 | 15.8% | 5.9% | ||
| Q2 24 | 23.7% | 10.2% |
每股收益（稀释后）BIIBNOV
| Q1 26 | — | $0.05 | ||
| Q4 25 | $-0.35 | $-0.20 | ||
| Q3 25 | $3.17 | $0.11 | ||
| Q2 25 | $4.33 | $0.29 | ||
| Q1 25 | $1.64 | $0.19 | ||
| Q4 24 | $1.82 | $0.40 | ||
| Q3 24 | $2.66 | $0.33 | ||
| Q2 24 | $4.00 | $0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.3B |
| 总债务越低越好 | $6.3B | $1.7B |
| 股东权益账面价值 | $18.3B | — |
| 总资产 | $29.4B | $11.1B |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势，按日历期对齐
现金及短期投资BIIBNOV
| Q1 26 | — | $1.3B | ||
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $985.0M | ||
| Q2 24 | — | $827.0M |
总债务BIIBNOV
| Q1 26 | — | $1.7B | ||
| Q4 25 | $6.3B | $1.7B | ||
| Q3 25 | $6.3B | $1.7B | ||
| Q2 25 | $6.3B | $1.7B | ||
| Q1 25 | $4.5B | $1.7B | ||
| Q4 24 | $6.3B | $1.7B | ||
| Q3 24 | $4.5B | $1.7B | ||
| Q2 24 | $6.3B | $1.7B |
股东权益BIIBNOV
| Q1 26 | — | — | ||
| Q4 25 | $18.3B | $6.3B | ||
| Q3 25 | $18.2B | $6.5B | ||
| Q2 25 | $17.6B | $6.5B | ||
| Q1 25 | $17.0B | $6.4B | ||
| Q4 24 | $16.7B | $6.4B | ||
| Q3 24 | $16.4B | $6.5B | ||
| Q2 24 | $15.9B | $6.4B |
总资产BIIBNOV
| Q1 26 | — | $11.1B | ||
| Q4 25 | $29.4B | $11.3B | ||
| Q3 25 | $29.2B | $11.3B | ||
| Q2 25 | $28.3B | $11.4B | ||
| Q1 25 | $28.0B | $11.3B | ||
| Q4 24 | $28.0B | $11.4B | ||
| Q3 24 | $28.3B | $11.4B | ||
| Q2 24 | $26.8B | $11.3B |
负债/权益比BIIBNOV
| Q1 26 | — | — | ||
| Q4 25 | 0.34× | 0.27× | ||
| Q3 25 | 0.35× | 0.27× | ||
| Q2 25 | 0.36× | 0.27× | ||
| Q1 25 | 0.27× | 0.27× | ||
| Q4 24 | 0.38× | 0.27× | ||
| Q3 24 | 0.28× | 0.27× | ||
| Q2 24 | 0.40× | 0.27× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | — |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $51.0M |
| 自由现金流率自由现金流/营收 | 20.5% | 2.5% |
| 资本支出强度资本支出/营收 | 1.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.1B | $876.0M |
8季度趋势，按日历期对齐
经营现金流BIIBNOV
| Q1 26 | — | — | ||
| Q4 25 | $511.9M | $573.0M | ||
| Q3 25 | $1.3B | $352.0M | ||
| Q2 25 | $160.9M | $191.0M | ||
| Q1 25 | $259.3M | $135.0M | ||
| Q4 24 | $760.9M | $591.0M | ||
| Q3 24 | $935.6M | $359.0M | ||
| Q2 24 | $625.8M | $432.0M |
自由现金流BIIBNOV
| Q1 26 | — | $51.0M | ||
| Q4 25 | $468.0M | $472.0M | ||
| Q3 25 | $1.2B | $245.0M | ||
| Q2 25 | $134.3M | $108.0M | ||
| Q1 25 | $222.2M | $51.0M | ||
| Q4 24 | $721.6M | $473.0M | ||
| Q3 24 | $900.6M | $277.0M | ||
| Q2 24 | $592.3M | $350.0M |
自由现金流率BIIBNOV
| Q1 26 | — | 2.5% | ||
| Q4 25 | 20.5% | 20.7% | ||
| Q3 25 | 48.4% | 11.3% | ||
| Q2 25 | 5.1% | 4.9% | ||
| Q1 25 | 9.1% | 2.4% | ||
| Q4 24 | 29.4% | 20.5% | ||
| Q3 24 | 36.5% | 12.6% | ||
| Q2 24 | 24.0% | 15.8% |
资本支出强度BIIBNOV
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 4.4% | ||
| Q3 25 | 1.8% | 4.9% | ||
| Q2 25 | 1.0% | 3.8% | ||
| Q1 25 | 1.5% | 4.0% | ||
| Q4 24 | 1.6% | 5.1% | ||
| Q3 24 | 1.4% | 3.7% | ||
| Q2 24 | 1.4% | 3.7% |
现金转化率BIIBNOV
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.73× | 8.38× | ||
| Q2 25 | 0.25× | 1.77× | ||
| Q1 25 | 1.08× | 1.85× | ||
| Q4 24 | 2.85× | 3.69× | ||
| Q3 24 | 2.41× | 2.76× | ||
| Q2 24 | 1.07× | 1.91× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
NOV
| Energy Equipment | $1.2B | 58% |
| Energy Products and Services | $897.0M | 44% |
